214 related articles for article (PubMed ID: 28455584)
1. Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
Nishijima-Futami Y; Minami S; Futami S; Koba T; Higashiguchi M; Tamiya M; Suzuki H; Hirashima T; Komuta K; Kijima T
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1215-1220. PubMed ID: 28455584
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
Yamada K; Ichiki M; Takahashi K; Hisamatsu Y; Takeoka H; Azuma K; Shukuya T; Nishikawa K; Tokito T; Ishii H; Hoshino T
Cancer Chemother Pharmacol; 2016 Sep; 78(3):501-7. PubMed ID: 27402398
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Nishino K; Imamura F; Kumagai T; Katakami N; Hata A; Okuda C; Urata Y; Hattori Y; Tachihara M; Yokota S; Nishimura T; Kaneda T; Satouchi M; Morita S; Negoro S
Lung Cancer; 2015 Aug; 89(2):146-53. PubMed ID: 26093793
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Tamiya A; Tamiya M; Shiroyama T; Saijo N; Nakatani T; Minomo S; Tsuji T; Takeuchi N; Omachi N; Kurata K; Suzuki H; Okamoto N; Okishio K; Hirashima T; Atagi S
Med Oncol; 2015 Mar; 32(3):40. PubMed ID: 25616723
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
[TBL] [Abstract][Full Text] [Related]
6. Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
Niho S; Ohe Y; Ohmatsu H; Umemura S; Matsumoto S; Yoh K; Goto K
Lung Cancer; 2017 Jun; 108():66-71. PubMed ID: 28625650
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
Kuyama S; Ochi N; Bessho A; Hotta K; Ikeda G; Kishino D; Kubo T; Harada D; Fujimoto N; Nakanishi M; Umeno T; Okada T; Chikamori K; Yamagishi T; Ohashi K; Ichihara E; Takigawa N; Tanimoto M; Kiura K
Lung Cancer; 2017 Oct; 112():188-194. PubMed ID: 29191594
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
Urata Y; Okamoto I; Takeda M; Hattori Y; Okuno K; Shimada T; Kurata T; Kaneda H; Miyazaki M; Terashima M; Tanaka K; Morita S; Nakagawa K; Negoro S; Satouchi M
Cancer; 2013 Jun; 119(12):2275-81. PubMed ID: 23558513
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
[TBL] [Abstract][Full Text] [Related]
11. Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.
Yang L; Yang S; Liu Y; Li J; Hu X; Wang Y; Zhang Y; Wang Y
Thorac Cancer; 2018 Jun; 9(6):693-698. PubMed ID: 29655198
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
Chihara Y; Yoshimura A; Date K; Takemura Y; Tamiya N; Kohno Y; Imabayashi T; Takeuchi M; Kaneko Y; Yamada T; Ueda M; Arimoto T; Uchino J; Iwasaki Y; Takayama K
Oncologist; 2019 Aug; 24(8):1033-e617. PubMed ID: 31040252
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer.
Kaira K; Tomizawa Y; Yoshino R; Miura Y; Yoshii A; Iwasaki Y; Koga Y; Ono A; Hisada T; Minato K; Sato K; Kazama T; Ishihara S; Kohyama K; Fueki N; Saito R; Sunaga N
Lung Cancer; 2013 Oct; 82(1):103-8. PubMed ID: 23927884
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102.
Yokoi T; Minami S; Shiroyama T; Koba T; Torii Y; Sugimoto H; Niki M; Mori M; Morimura O; Hirashima T; Komuta K; Kijima T
Intern Med; 2019 May; 58(10):1405-1410. PubMed ID: 30713297
[TBL] [Abstract][Full Text] [Related]
16. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
Ichinose Y; Yoshimori K; Sakai H; Nakai Y; Sugiura T; Kawahara M; Niitani H
Clin Cancer Res; 2004 Dec; 10(23):7860-4. PubMed ID: 15585618
[TBL] [Abstract][Full Text] [Related]
17. An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
Kaira K; Imai H; Souma R; Sakurai R; Miura Y; Sunaga N; Kasahara N; Tsukagoshi Y; Koga Y; Kitahara S; Kotake M; Minato K; Naruse I; Fukushima Y; Hisada T; Ishizuka T
Anticancer Res; 2019 May; 39(5):2483-2491. PubMed ID: 31092443
[TBL] [Abstract][Full Text] [Related]
18. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
Goya H; Kuraishi H; Koyama S; Ichiyama T; Yoshiike F; Hirai K; Agatsuma T; Tateishi K; Kanda S; Yamamoto H; Kubo K; Koizumi T
Cancer Chemother Pharmacol; 2012 Nov; 70(5):691-7. PubMed ID: 22941346
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
